Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A RANDOMIZED DOUBLE-BLIND PHASE III STUDY OF IBRUTINIB DURING AND FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION VERSUS PLACEBO IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA OF THE ACTIVATED B-CELL SUBTYPE
A Phase 1 Study of SynKIR-310, Autologous T cells Transduced with CD19 KIR-CAR, in Participants with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Study Type: Treatment
Phase: I
NCTID: NCT06544265
Principal Investigator:
Joseph McGuirk
A Multicenter, Open-label, Phase II Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell malignancies waveLINE-006
Study Type: Treatment
Phase: II
NCTID: NCT05458297
Principal Investigator:
Marc Hoffmann
Phase II Study of Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma
Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 Directed CAR T-Cell Therapy
Study Type: Other
Phase: N/A
NCTID: NCT02445222
Principal Investigator:
Gary Myers
Phase II Study of Bendamustine and Rituximab plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age
Study Type: Treatment
Phase: II
NCTID: NCT03834688
Principal Investigator:
Marc Hoffmann
A Phase I Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T-Cells MT-601 Administered to Patients with Relapsed or refractory Non-Hodgkin Lymphoma NHL [APOLLO]
Study Type: Treatment
Phase: I
NCTID: NCT05798897
Principal Investigator:
Haitham Abdelhakim
An Open-Label, Phase I, Multi-Center Study to Determine in Relapsed/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome or B-Cell Non-Hodgkin Lymphoma Patients the Recommended Dose of CYAD-02 After A Non-Myeloablative Preconditioning Chemotherapy Followed By A Potential CYAD-02 Consolidation Cycle for Non-Progressive Patients CYCLE-1 ? CYAD-02 NKG2D CAR-T Clinical dEvelopment
A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
Study Type: Treatment
Phase: I/II
NCTID: NCT03323151
Principal Investigator:
Marc Hoffmann